We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
|Bid||1.75 x 200|
|Ask||1.97 x 200|
|Day's Range||1.78 - 1.93|
|52 Week Range||0.90 - 3.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
MIAMI, March 22, 2018-- Veru Inc., a biopharmaceutical company focused on urology and oncology, announced that the U.S. Food and Drug Administration granted its application for a small business waiver ...
MIAMI, March 16, 2018-- Veru Inc., a biopharmaceutical company focused on urology and oncology, announced that data from a preclinical study of VERU-111, a novel oral alpha and beta tubulin inhibitor, ...
MIAMI, March 14, 2018-- Veru Inc. today announced that that the company will present at the Oppenheimer 28 th Annual Healthcare Conference at 1:35 p.m. ET on Wednesday, March 21, 2018 at the Westin New ...
MIAMI, March 05, 2018-- Veru Inc. today announced that it has completed a $10 million“ synthetic” royalty financing on FC2 Female Condom ® product sales with SWK Holdings. Veru will use the funds to advance ...
--Company Advancing Multiple Drugs from Pipeline; First New Drug Application Remains on Track for Submission in 2018; Two Additional NDAs Expected to be Filed in 2019; Promising Oncology Drug Data Presented ...
NEW YORK, NY / ACCESSWIRE / February 14, 2018 / Veru Inc. (NASDAQ: VERU ) will be discussing their earnings results in their Q1 Earnings Call to be held on February 14, 2018 at 8:00 AM Eastern Time. To ...
MIAMI, Feb. 07, 2018-- Veru Inc. today announced that on February 14, 2018, the company will report financial results for its fiscal 2018 first quarter ended December 31, 2017, before the market opens. ...
MIAMI, Feb. 06, 2018-- Veru Inc. today announced data from a pre-clinical study of VERU-111, a novel oral alpha and beta tubulin inhibitor, showing potent activity against paclitaxel sensitive and resistant ...
LONDON, UK / ACCESSWIRE / January 16, 2018 / Active-Investors.com has just released a free earnings report on Veru Inc. (NASDAQ: VERU ). If you want access to this report all you need to do is sign up ...
Full Time Employees : 175
Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. Veru Inc. serves agencies, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.